FPT-SOFTWARE/SCSK-EU
19.4.2022 05:02:12 CEST | Business Wire | Press release
Vietnam’s leading Digital Transformation services provider FPT Software has recently unveiled its partnership with SCSK Europe, a subsidiary of the Japan-based system integrator SCSK Corporation. The collaboration affirms FPT Software’s robotic process automation (RPA) expertise and further expands its foothold in the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005262/en/
Applying “Fast Automation” framework, FPT Software has successfully helped SCSK Europe streamline six internal processes by deploying its award-winning RPA platform akaBot in four weeks. The offshore team then provided a comprehensive understanding of RPA’s benefits and armed SCSK employees with the necessary skills and mentality for the upcoming changes with the emergence of digital transformation. Following their internal success, SCSK Europe introduced FPT Software’s akaBot to their clients in the Chemical and Agriculture industries to help replace 100 percent human effort in their data extraction and loan credits approval processes.
"RPA is a powerful tool to resolve the bottleneck in business processes, delivering a much streamlined and efficient workflow. We believe that we can always extend the automation horizons even more by integrating RPA robots with other intelligent technologies,” said Masatoshi Chiba – General Manager, SCSK EU.
“With that expectation in mind, we decided to partner with akaBot, one of the leading vendors in developing hyper-automation solutions from FPT. Since 2018, we have established MOU for the comprehensive partnership to seek to supply a wider range of services and solutions and to expand our operations in the global through this partnership with FPT," Masatoshi Chiba further shared.
According to FPT Software Chief Operating Officer Tran Dang Hoa, the collaboration "paved the way for FPT Software’s expansion in robotic automation and digital transformation in the EU and on a global scale."
"Like SCSK, more and more firms worldwide are adopting RPA and hyper-automation to enhance operations," Tran Dang Hoa said. "As a global top 30 RPA solution provider, we aspire to accompany businesses to overcome pressing challenges, boost their productivity and save costs," he added.
FPT Software and SCSK’s partnership dates back to 2018 when the two cooperated in supporting the overseas expansion of Japanese companies, especially in financial and automotive systems development. Both sides joined forces in providing IT Services and business development through the Asia Pacific operations of major SCSK’s shareholder – Sumitomo Corporation.
First entering the European market in 2008, FPT Software has established seven offices and development centers, and is determined to penetrate further with digital transformation as the key driving force. The global IT firm targeted this strategic area as its first port for capital commitment in the value of 100 million dollars in the upcoming years, with the UK and Germany as two major geographies.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with USD 632.5 million in revenue and 22,500 employees in 26 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com .
About SCSK EU
SCSK Europe Ltd. was established in London in 1990 as a fully-owned subsidiary of SCSK Corporation, one of Japan's leading IT service companies with more than 14,000 employees. We are One Stop IT Service Provider and a proven strategic business partner to Japanese-related corporations operating in EMEA/CIS providing various IT Solutions including RPA. For further information, please visit SCSK Europe Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom